Skip to Content
Morningstar

CVS Health Corp CVS Stock Quote

Morningstar Rating
| Rating as of

Morningstar‘s Stock Analysis CVS

Valuation
Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Investor
Is it the right time to buy or sell?
Find out with Morningstar Investor

1-Star Price

INVESTOR

5-Star Price

INVESTOR

Economic Moat

INVESTOR

Capital Allocation

INVESTOR

CVS Adding Home Health and Value-Based Care Capabilities With Signify Deal; Shares Undervalued

Julie Utterback, CFA Senior Equity Analyst

Analyst Note

| Julie Utterback, CFA |

Narrow-moat CVS Health announced the $8 billion acquisition of Signify Health, which we view as the first step in its acquisition strategy within care delivery. While we appreciate the benefits expected from the Signify acquisition, it does not change our view of the firm's moat or our $113 fair value estimate. CVS shares remain mildly undervalued.

Unlock Our Full Analysis With Morningstar Investor

Key Statistics CVS

More

Company Profile CVS

Business Description

Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.

Contact
One CVS Drive
Woonsocket, RI, 02895
T +1 401 765-1500
Sector Healthcare
Industry Healthcare Plans
Most Recent Earnings Jun 30, 2022
Fiscal Year End Dec 31, 2021
Employees 300,000

Related News CVS

Commentary

What Are the Risks of Social Washing?

Investors should push for greater disclosure about the management of social issues.
Emma Williams
Investing Specialists

Top 10 Holdings of Our Ultimate Stock-Pickers' Index

Eden Alemayehu
Investing Specialists

Our Ultimate Stock-Pickers' Top 10 High-Conviction Purchases

Several funds see value in technology and communication services.
Justin Pan
Stock Strategist Industry Reports

Healthcare Policy Changes Could Result in Opportunities

Expanded insurance rolls would be good news for the managed-care organizations and service providers we cover.
Julie Utterback
Stock Analyst Update

CVS Health Has Q2 That Beats Expectations

However, investors may be disappointed that CVS backed off its 2022 goal of double-digit earnings growth.
Julie Utterback
Fund Spy

8 of Our Favorite Little Funds

Here are some under-the-radar gems.
Russel Kinnel
Stock Analyst Update

Supreme Court Ruling to Uphold ACA

This decision adds certainty to related health insurance programs.
Julie Utterback
Stock Analyst Update

CVS Delivers Strong Q1 and Increases 2021 Outlook

We think shares still look undervalued.
Julie Utterback
US Videos

Drugmakers and Managed-Care Firms Are Poised for Growth

These areas remain undervalued even though valuations for the overall healthcare sector look a bit high.
Damien Conover
Our Picks

33 Undervalued Stocks for the Second Quarter

Here are our analysts' top ideas in each sector for the coming quarter.
Susan Dziubinski
Stock Strategist

Why We Like Walgreens, But at a Better Price

Strong international performance and pharmacy margins helped in the first quarter.
Julie Utterback
Quarter-End Insights

Drugmakers and Managed-Care Firms Still Look Undervalued

We don't expect any major changes to U.S. healthcare policy.
Damien Conover
Our Picks

5 Stocks to Spend Your Stimulus Check On

These familiar brands are all undervalued today.
Susan Dziubinski
Stock Analyst Update

CVS Guides Cautiously for 2021 After Strong 2020

The narrow-moat company beat our expectations, and we are keeping our fair value estimate at $92 per share.
Julie Utterback
Stock Strategist Industry Reports

COVID-19 Vaccine Distribution and Herd Immunity to End Pandemic

Successful vaccine development and rollout will boost industry goodwill and reduce ESG risk, but we’re keeping our valuations steady.
Karen Andersen
US Videos

Healthcare Outlook: Coronavirus at Center Stage

And some undervalued stocks that capture our attention.
Damien Conover
Stock Strategist Industry Reports

What a Democratic Sweep Means for Healthcare

We think the insurers could be most influenced by potential reforms.
Julie Utterback
Our Picks

33 Undervalued Stocks for 2021

Here are our analysts' top ideas in each sector for the new year.
Susan Dziubinski
Quarter-End Insights

In Healthcare, Drugmakers and Managed-Care Firms Look Attractive

We don't expect major policy reforms now that the dust has settled on the elections.
Damien Conover
Stock Strategist

What Amazon's Pharmacy Launch Means for CVS and Walgreens

It could bring more competition, but not enough to change our valuations.
Julie Utterback